DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
Trial details
- Registry ID
- NCT07024693
- Drugs studied
- DT-168
TrialRedline tracks 1 clinical trial sponsored by Design Therapeutics, Inc.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal DystrophyNCT07024693 | DT-168 | Recruiting | 2027-12Estimated |
Names as written in the registry records.
NCT07024693 · Design Therapeutics, Inc.
Before: 28 participants (planned). After: 70 participants (planned).
Before: Sep 2026. After: Dec 2027.